Midostaurin companion diagnostic - Invivoscribe/Novartis Oncology
Alternative Names: FLT3 companion diagnostic; LeukoStratCDx FLT3 Mutation Assay; PKC 412 companion diagnostic - Invivoscribe/NovartisLatest Information Update: 03 Dec 2018
At a glance
- Originator Takara Bio
- Developer Invivoscribe Technologies; Novartis Oncology
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Acute myeloid leukaemia
Most Recent Events
- 29 Nov 2018 Launched for Acute myeloid leukaemia (Diagnosis) in European Union (unspecified route) before November 2018
- 29 Nov 2018 Registered for Acute myeloid leukaemia (Diagnosis) in European Union, Norway, Iceland, Liechtenstein (unspecified route) before November 2018
- 29 Nov 2018 Invivoscribe announces intention to launch to gilteritinib companion diagnostic in the US for Acute myeloid leukaemia